In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies

Keywords : In Vitro Diagnostic, in vitro diagnostic reagent, diagnostic reagent , POC, Flow Cytometry, microbiology, IVD, in vitro diagnostics, radioimmunoassay, Blood Grouping , hematology, IVD test, cytology

It is commonly asserted that in vitro diagnostics is a recession-proof industry. Kalorama Information's lead diagnostic analyst Shara Rosen tests that assumption and provides strategic conclusions in Shara Rosen's new report In Vitro Diagnostics in a Recession. The economic problems that began slowing the U.S. economy keep spreading, with Europe and Japan following America into recession. The US is experiencing high unemploy...

More »

It is commonly asserted that in vitro diagnostics is a recession-proof industry. Kalorama Information's lead diagnostic analyst Shara Rosen tests that assumption and provides strategic conclusions in Shara Rosen's new report In Vitro Diagnostics in a Recession.


The economic problems that began slowing the U.S. economy keep spreading, with Europe and Japan following America into recession. The US is experiencing high unemployment rate and increased numbers of uninsured workers. But what impact is the downturn having on in vitro diagnostic companies? What are the best areas of IVD and the best world markets? How should companies price and market their products? What are key companies in the market doing at this time?
Among the topics covered in this report:

• Current Market Estimates for Major Categories of IVD.


• Category Forecasts to 2014


• Hospital Woes, Uninsured Patients, Payor Stress, and Other Trends industry observers need to know about.


• Current World Economic Conditions US, Europe and Emerging Markets
• Obama Administration Healthcare Reform Boom or Bust for IVD?


• Mergers and Acquisitions: Abbot - Ibis, QIAGEN - Corbett Life Science, J&J / Amic and several other competitive moves.


• Collaborations: Luminex and BD Tripath, Geisinger Health System and Celera, Sysmex and Epigenomics and other partnerships enacted as companies pool limited resources.


• Market Expansions: StatSensor Creatinine Meter (TM), Dako and BMS partnership and Others.


• New Testing Products Launched: BD Focal Point, Aureon's Prostate Px+, New Abbott Marker for AKI and other new tests.


• Lab Service Commercialization Activities


• Lab IT Activity and the Involvement of High Tech Players such as Google and IBM.


• Success Strategies That are Working in 2009

Shara Rosen goes beyond just assessing the market and presents actions that IVD companies can take to assure growth in uncertain times. The report has a special focuses on developments in the United States since this is the largest single market for IVD products, but there is discussion of emerging world markets as well.
The following companies who have engaged in relevant competitive activities in recent months were profiled in this report:

• Abbott Diagnostics


• Beckman Coulter Inc.


• Becton, Dickinson and Company (BD)


• bioMerieux Inc.


• Celera Corporation


• Cellestis Ltd


• Cepheid


• Clarient Inc. (formerly ChromaVision)


• deCode Genetics Inc.


• Genomic Health


• Gen-Probe Inc.


• Immucor, Inc.


• Inverness Medical Innovations


• Luminex Corporation


• Monogram Biosciences, Inc.


• Nanogen


• Ortho Clinical Diagnostics (OCD)


• Qiagen N.V.


• Quidel Corporation


• Roche Diagnostics


• Seegene, Inc.


• Sequenom, Inc.


• Siemens Medical Solutions Diagnostics


• Sysmex Corporation


• Vermillion/Ciphergen Biosystems Inc.

This Kalorama Information report is a work of primary research. Although secondary sources were used, the analyst's years of experience, interviews with industry experts and the latest findings of the 2009 Diagnostic Marketing Association Conference in Chicago IL were part of this report's foundation.

In Vitro Diagnostic Industry

CHAPTER ONE: Executive Summary

• Scope and Methodology


• Market Trends


• World Demand for Diagnostics


• Keys to Success

CHAPTER TWO: Introduction

• Background


• Marketing in a recession - what the experts say about the 4Ps


• Obama’s new deal - boom and bust


• Musings on what form a reformed U.S. system might take


• Status quo and future - impressing investors in a bear market

CHAPTER THREE: Market Trends/Demand Analysis

• Hospital financing


• The role of new deal for the insured, uninsured and underinsured


• Payer response to economic stress


• Demand for esoteric tests


• World market for IVD tests and services




• 2009 Market Estimates (N. America, EU West Europe, Japan, China, Latin America, India, EU East Europe, ROW)


• 2014 Market Forecasts (N. America, EU West Europe, Japan, China, Latin America, India, EU East Europe, ROW)


• Economic Conditions in United States of America


• Economic Conditions in Europe


• Economic Conditions in Japan


• Economic Conditions in China

CHAPTER FOUR: Market Overview/Supply Analysis

• Market Analysis, revenue estimates 2007 - 2015


• IVD Sectors Revenues




• Clinical Chemistry,


• Immunoassays - non isotopic Infectious Diseases


• Other Immunos


• Blood Bank Screening


• Hematology


• Microbiology (ID/AST)


• Molecular Microbiology


• Radioimmunoassays


• Coagulation


• Histology/Cytology


• Nucleic Acid Assays


• Blood Grouping/Typing


• Blood Bank Molecular


• Flow Cytometry


• POC -OTC diabetes


• POC -OTC other


• POC -Professional/Hospital




• IVD Events




• New Tests and Technologies




• Abbott Diagnostics


• Adnavance Technologies


• Arbor Vita Corporation


• Arcxis Biotechnologies and Roche


• Assay Designs


• Aureon Laboratories


• Bayer Healthcare


• BD Diagnostics


• bioMérieux


• BRAHMS


• Caris Diagnostics


• CISBIO Bioassays


• Decision Biomarkers


• DexCom


• Diagnostic HYBRIDS


• Fujirebio Diagnostics


• GeneNews


• InVivoScribe Technologies


• Network Biosystems




• Acquisitions, Mergers




• Abbott Diagnostics-Ibis


• Beckman Coulter-Nephromics


• Exiqon A/S-Oncotech


• GE Healthcare-Whatman


• Others




• Collaborations


• Market Expansion Activities


• Lab Services


• Lab Information




• Google


• IBM


• Intel Corporation


• General Data Company Technology

CHAPTER FIVE: Company Profiles

• Abbott Diagnostics


• Beckman Coulter Inc.


• Becton, Dickinson and Company (BD)


• bioMerieux Inc.


• Celera Corporation


• Cellestis Ltd


• Cepheid


• Clarient Inc. (formerly ChromaVision)


• deCode Genetics Inc.


• Genomic Health


• Gen-Probe Inc.


• Immucor, Inc.


• Inverness Medical Innovations


• Luminex Corporation


• Monogram Biosciences, Inc.


• Nanogen


• Ortho Clinical Diagnostics (OCD)


• Qiagen N.V.


• Quidel Corporation


• Roche Diagnostics


• Seegene, Inc.


• Sequenom, Inc.


• Siemens Medical Solutions Diagnostics


• Sysmex Corporation


• Vermillion/Ciphergen Biosystems Inc.

CHAPTER SIX: Conclusion

• Pricing Strategy


• Marketing Strategy


• Supply and Demand

TABLE OF EXHIBITS



CHAPTER ONE: EXECUTIVE SUMMARY

• Figure 1-1: Growth Rates Compared: World Regions

CHAPTER TWO: INTRODUCTION

• Table 2-1: Selected IVD Venture Investments

CHAPTER THREE: MARKET TRENDS/DEMAND ANALYSIS

• Table 3-1: Number of People Worldwide Who Get Chronic Diseases Every Year


• Table 3-2: Percent Change in Industrial Productivity, by Country or Region, December 2007 to December 2008


• Table 3-3: Worldwide In Vitro Diagnostic Reagent Sales by country, 2009-2014


• Table 3-4: Europe Unemployment Rates and % change in GDP

CHAPTER FOUR: Market Overview/Supply Analysis

• Table 4-1

Worldwide In Vitro Diagnostic Reagent Sales by Product Segment, 2009-2014 (Clinical Chemistry, Immunoassays, Blood Bank Screening, Hematology, Microbiology, Radioimmunoassays, Coagulation, Histology/Cytology, Nucleic Acid Assays, Blood Grouping/Typing, Blood Bank Molecular, Flow Cytometry, POC OTC diabetes, POC, OTC Other, POC, Professional/Hospital)

CHAPTER SIX: Conclusion

• Table 6-1: Pricing Structures That Create Value for the Customer